CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) to Post Q1 2025 Earnings of ($0.36) Per Share, HC Wainwright Forecasts

CollPlant Biotechnologies Ltd. (NASDAQ:CLGN) – Equities research analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for shares of CollPlant Biotechnologies in a research report issued to clients and investors on Friday, April 5th. HC Wainwright analyst S. Ramakanth forecasts that the company will earn ($0.36) per share for the quarter. HC Wainwright has a “Buy” rating and a $11.00 price objective on the stock. The consensus estimate for CollPlant Biotechnologies’ current full-year earnings is ($0.57) per share. HC Wainwright also issued estimates for CollPlant Biotechnologies’ Q2 2025 earnings at $0.31 EPS, Q3 2025 earnings at ($0.32) EPS and Q4 2025 earnings at ($0.30) EPS.

CollPlant Biotechnologies Trading Up 2.2 %

CLGN opened at $5.23 on Monday. CollPlant Biotechnologies has a 1-year low of $4.22 and a 1-year high of $8.90. The stock has a market cap of $59.83 million, a PE ratio of -8.16 and a beta of 0.24. The stock’s fifty day simple moving average is $5.32 and its 200 day simple moving average is $5.45.

Institutional Investors Weigh In On CollPlant Biotechnologies

A number of institutional investors have recently made changes to their positions in the company. Villere ST Denis J & Co. LLC raised its position in shares of CollPlant Biotechnologies by 20.4% in the fourth quarter. Villere ST Denis J & Co. LLC now owns 361,293 shares of the company’s stock valued at $2,309,000 after buying an additional 61,120 shares in the last quarter. LPL Financial LLC bought a new stake in shares of CollPlant Biotechnologies during the 2nd quarter worth approximately $361,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of CollPlant Biotechnologies during the 2nd quarter worth approximately $189,000. Jane Street Group LLC acquired a new stake in shares of CollPlant Biotechnologies during the 3rd quarter worth approximately $90,000. Finally, UBS Group AG increased its stake in CollPlant Biotechnologies by 119.1% in the second quarter. UBS Group AG now owns 7,514 shares of the company’s stock valued at $60,000 after acquiring an additional 4,085 shares during the last quarter. Institutional investors own 21.69% of the company’s stock.

CollPlant Biotechnologies Company Profile

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, and Europe. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.